Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

Subcutaneous injections offer various benefits over IV infusions, including improved comfort, convenience, and ease of treatment. However, there is no one-size-fits-all approach to cancer treatment.

CUTX-101 is a copper replacement therapy that is administered via subcutaneous injection. ... which evaluated 129 patients with Menkes disease treated with subcutaneous CUTX-101 1450mcg ...

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.Nivolumab and ...

Ocrevus subcutaneous injection was non-inferior to Ocrevus IV infusion as measured by Ocrevus levels in the blood of patients (area under the serum concentration time curve) from day 1 to 12 weeks ...

Ocrevus' Subcutaneous Injection: Advancing Multiple Sclerosis Treatment. Roche has announced positive results from its Phase III OCARINA II trial for Ocrevus (ocrelizumab) ...

Local anesthesia is achieved through the subcutaneous injection and infiltration of anesthetic agents at the margins of a wound. In contrast, a peripheral nerve block is achieved through the ...